Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 7/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CLK2 | P49760 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12270172 | 0.85 | LTA4H (0.43) | LTA4HCHRNA3CHRNB4 | |
| SCHEMBL12319408 | 0.82 | LTA4H (0.35) | LTA4H | |
| SCHEMBL16151498 | 0.81 | LTA4H (0.33) | LTA4H | |
| SCHEMBL12271149 | 0.73 | KDM4E (0.41) | — | |
| SCHEMBL16151501 | 0.69 | LTA4H (0.33) | LTA4HCHRNA3CHRNB4 | |
| SCHEMBL13383566 | 0.65 | LTA4H (0.48) | LTA4HCHRNA3CHRNB4 | |
| SCHEMBL12266365 | 0.65 | LTA4H (0.48) | LTA4HCHRNA3CHRNB4 | |
| SCHEMBL12271070 | 0.65 | LTA4H (0.45) | LTA4HCHRNA3 | |
| SCHEMBL13383606 | 0.64 | LTA4H (0.52) | LTA4HCHRNA3CHRNB4 | |
| SCHEMBL12266393 | 0.64 | LTA4H (0.52) | LTA4HCHRNA3CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853424-B2 | Protein cross-linking inhibitor | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2014-10-07 | — | — | US | disclosed |
| US-8853424-B2 | Protein cross-linking inhibitor | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2014-10-07 | — | — | US | disclosed |
| US-20110212919-A1 | PROTEIN CROSS-LINKING INHIBITOR | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-09-01 | — | — | US | disclosed |
| US-20110212919-A1 | PROTEIN CROSS-LINKING INHIBITOR | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-09-01 | — | — | US | disclosed |
| WO-2010018837-A2 | PROTEIN CROSS-LINKING INHIBITOR | 独立行政法人科学技術振興機構 (JP) | 2010-02-18 | — | — | WO | disclosed |
| WO-2010018836-A2 | POLYGLUTAMINE AGGREGATION INHIBITOR | 独立行政法人科学技術振興機構 (JP) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212919-A1 | PROTEIN CROSS-LINKING INHIBITOR | BAZ2B, PRMT1, BRIX1 | LTA4H 4297/4885CHRNA3 3427/4885CHRNB4 2566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.